On October 2, 2025, we had the honour to attend an incredible event 🏆 #LSBCAwards organized by @LifeSciences_BC: a true celebration of #leadership, #innovation, and #impact.

Where is the future of life sciences headed in BC? Join industry leaders for a Life Sciences Panel exploring the trends, opportunities, and collaborations shaping the future of the sector. Learn more: investvancouver.ca/resources…

The pro-inflammatory role of microglia is considered a key driver of Alzheimer's disease. Today @NeuroCellPress discovery of an epigenetic regulator of microglial mitochondria in the experimental model that may be amenable as a target for therapy or prevention cell.com/neuron/fulltext/S08…

The first participant to receive partial cellular reprogramming for eye disease (advanced glaucoma) in a pilot study of 12 patients was treated. Using 3 of the 4 Yamanaka stem cell factors to potentially achieve cellular rejuvenation @Nature nature.com/articles/d41586-0…

A graph neural network framework enables individualized genetic risk prediction at the single-cell level go.nature.com/3H6pAlr rdcu.be/fmbnx

Structural motif search across the protein universe with Folddisco go.nature.com/4g8lCb0

Two of the most powerful technologies we've ever known—CRISPR human embryo editing and self-improving A.I.—are getting actualized, and carry known and unforeseen risks nytimes.com/2026/06/04/scien… wsj.com/tech/ai/anthropic-ur… @AnthropicAI

‼️ Landmark #lungcancer research published today in Cell Scientists at the Francis Crick Institute and UCL have discovered a 14-protein blood signature that predicts lung cancer more than 5 years before diagnosis, works in never-smokers, and could identify who benefits from prevention treatment. People with high levels of these proteins were the ones who actually benefited from a drug to damp that inflammation down, cutting their lung cancer risk nearly in half. This could finally give us something lung cancer has never had: a way to prevent it in the people most at risk. doi.org/10.1016/j.cell.2026.… #LCSM

Ocrelizumab, a monoclonal antibody, is already approved for people with relapsing or primary progressive multiple sclerosis. In The Lancet, two phase 3 trials suggest a higher dose of ocrelizumab did not further reduce the risk of disability progression; however, data confirm the favourable benefit–risk profile of 600 mg ocrelizumab. Read more: spkl.io/60187BSEg

Bladder cancer is the fifth most common cancer in Canada. Drs. Peter Black and Wilfred Jefferies from @UBC and @EyamHealth are collaborating on a genomics informed approach to designing a #BladderCancer vaccine. Learn more about this @GenomeBC funded collab: bit.ly/4aupzmN

Decoding the origins of cellular self-organization for engineered biology go.nature.com/4e1m3Br

With aging, cells lose their identity and undergo a mesenchymal drift. Reversing this drift may be a way to mitigate aging and promote healthspan. A new @CellCellPress review cell.com/cell/fulltext/S0092…

Big progress vs cancer, folks. The kind of event curves from randomized trials that we've not seen before for a couple of the most deadly cancers. Congrats to the oncology research community for getting these trial done. #ASCO26, @ASCO

Just published @NEJM Marked and durable reduction of LDL cholesterol with one shot PCSK9 gene base editing @skathire nejm.org/doi/full/10.1056/NE…

The ramp up of cancer immunotherapy is remarkable. Now we're seeing vaccines achieve some cures or remissions in the most refractory cancers: pancreatic, melanoma, glioblastoma, renal, triple-negative breast cancer. ✓ out the new Ground Truths (link in profile)

What motivates you at work? Last year's chemistry laureate Omar Yaghi told us what motivates him in his scientific career: “It’s the thrill of discovery. I think we do science because we want to stimulate our mind. We also want recognition for our work. I think those two things are very important. But then beyond that, you want to do it to impact others. Discovery is the currency of influencing people’s way of thinking, of changing people’s lives for the better, impacting society in ways that were unprecedented before that discovery. So discovery is everything. It’s a thrill to me. I’m addicted to it. I wake up every day going to the lab, because a student might have made a discovery or an observation that may lead to a great discovery. It’s still in me, and I love it. I would never give it up for anything.” Read our full interview with Yaghi: nobelprize.org/prizes/chemis…

Nature research paper: A critical initialization for biological neural networks go.nature.com/4dWeixL

A beautiful cover @ScienceMagazine representing the way back origins of our immune system, by @yashastone w/ @ScienceVisuals science.org/content/article/…

Whether there is a real impact of GLP-1 drugs on cancer is unresolved. If confirmed, it could simply reflect weight loss or, as seen for other conditions (e.g. heart, kidney), weight loss independent effects. We need dedicated trials to resolve this important question. git link wsj.com/health/pharma/popula…

There are nearly 1.2 billion people living with mental health conditions worldwide, according to a new #GBD analysis. Explore the research ➡️ spkl.io/6011AhkHU @IHME_UW

It’s the final week to nominate for Life Sciences BC Awards! The Don Rix Lifetime Achievement Award celebrates an exceptional individual whose decades-long career has shaped the sector and inspired future generations. Submit nominations by May 8, 2026: lifesciencesbc.ca/awards-pag…